1. Scrip
  2. >>Leadership

Genfit Addresses Multiple Transition Issues With CEO Change

 
• By Joseph Haas

Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.

Transition Vision Strategy Execution Speedometer Plan 3d Illustration - Illustration
Pascal Prigent will position Genfit for the commercial stage • Source: Shutterstock

As Genfit SA prepares to shift from a clinical- to a commercial-stage company, Pascal Prigent was named the firm's new CEO on 2 September because he brings the right skill set to make the transition.

Prigent was recruited for the French biotech in May 2018, as executive VP of marketing and commercial development. His prior experience in marketing, sales and management at GlaxoSmithKline PLC and before that at Eli Lilly & Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.